MY-5445

SKU: orb1307997

Description

MY-5445 is a selective phosphodiesterase 5 (PDE5) inhibitor with a Ki of 1.3 µM. This compound is a research tool used in vitro and in vivo to study cGMP-mediated signaling pathways relevant to vascular biology and smooth muscle function.

Research Area

Metabolism Research

Key Properties

• CAS Number: 78351-75-4
• MW: 331.8
• Purity: 99.77% (May vary between batches)
• Formula: C₂₀H₁₄ClN₃
• SMILES: Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1
• Target: PDE
• Solubility: 10% DMSO+90% Corn Oil:2 mg/mL (6.03 mM);DMSO:40 mg/mL (120.55 mM)

Bioactivity

• Target IC50:
  PDE4:37 μM|PDE5:1.3 μM (Ki)|PDE5:6.7 μM
• In Vivo:
  I.p administration of 0.5-3 mg/kg twice a day for 15 days) produces significant relief of mechanical hypersensitivity.
• In Vitro:
  in ABCG2-overexpressing cells, MY-5445 selectively reverses ABCG2-mediated multidrug resistance. MY-5445 reverses ABCG2-mediated multidrug resistance (MDR) by potentiating the cytotoxicity of an ABCG2 substrate drug in ABCG2-overexpressing multidrug-resistant cancer cells, possibly by modulating the function and/or the protein expression of ABCG2. In the S1-M1-80 cell, MY-5445 (3 μM; 48 hours) substantially increases the topotecan-induced apoptosis.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

PDE4, N-(3-chlorophenyl)-4-phenylphthalazin-1-amine, neuropathic pain, neuropathic, Inhibitor, MY 5445, MY5445, MY-5445, inhibit, allodynia, aggregation, anticancer, Phosphodiesterase (PDE), PDE5, platelet

Compound Identifiers

PubChem CID

1348